
Publikationen von Eckhard Mandelkow
Alle Typen
Zeitschriftenartikel (32)
1.
Zeitschriftenartikel
24 (11), 9260 (2023)
Reversal of Tau-dependent cognitive decay by blocking adenosine A1 receptors: Comparison of transgenic mouse models with different levels of tauopathy. International Journal of Molecular Sciences 2.
Zeitschriftenartikel
59 (6), S. 3402 - 3413 (2022)
Assessment of the in vivo relationship between cerebral hypometabolism, Tau deposition, TSPO expression, and synaptic density in a tauopathy mouse model: a multi-tracer PET study. Molecular Neurobiology 3.
Zeitschriftenartikel
14, 13 (2019)
Functional networks are impaired by elevated tau-protein but reversible in a regulatable Alzheimer's disease mouse model. Molecular Neurodegeneration 4.
Zeitschriftenartikel
269 (8), S. 973 - 984 (2019)
Evaluation of the methoxy-X04 derivative BSC4090 for diagnosis of prodromal and early Alzheimer’s disease from bioptic olfactory mucosa. European Archives of Psychiatry and Clinical Neuroscience 5.
Zeitschriftenartikel
56 (5), S. 3751 - 3767 (2019)
Suppressing Tau aggregation and toxicity by an anti-aggregant Tau fragment. Molecular Neurobiology 6.
Zeitschriftenartikel
117, S. 189 - 202 (2018)
Glutamatergic nervous system degeneration in a C. elegans TauA152T tauopathy model involves pathways of excitotoxicity and Ca2+ dysregulation. Neurobiology of Disease 7.
Zeitschriftenartikel
1779, S. 99 - 111 (2018)
Purification and characterization of low-n tau oligomers. Methods in Molecular Biology 8.
Zeitschriftenartikel
18 (5), S. 3271 - 3281 (2018)
Reversible cation-selective attachment and self-assembly of human Tau on supported brain lipid membranes. Nano Letters 9.
Zeitschriftenartikel
37 (7), e98049 (2018)
Tau protein liquid-liquid phase separation can initiate tau aggregation. The EMBO Journal 10.
Zeitschriftenartikel
12, 88 (2017)
Anti-aggregant tau mutant promotes neurogenesis. Molecular Neurodegeneration 11.
Zeitschriftenartikel
57, S. 47 - 63 (2017)
Time course of Tau toxicity and pharmacologic prevention in a cell model of Tauopathy. Neurobiology of Aging 12.
Zeitschriftenartikel
14 (7), S. 742 - 752 (2017)
Inhibition of Tau protein aggregation by rhodanine-based compounds solubilized via specific formulation additives to improve bioavailability and cell viability. Current Alzheimer Research 13.
Zeitschriftenartikel
31 (12), S. 5137 - 5148 (2017)
Caenorhabditis elegans models of tauopathy. The FASEB Journal 14.
Zeitschriftenartikel
5, 91 (2017)
Atypical, non-standard functions of the microtubule associated Tau protein. Acta Neuropathologica Communications 15.
Zeitschriftenartikel
139 (7), S. 2639 - 2646 (2017)
A two-component adhesive: Tau fibrils arise from a combination of a well-defined motif and conformationally flexible interactions. Journal of the American Chemical Society 16.
Zeitschriftenartikel
292 (29), S. 12192 - 12207 (2017)
Axodendritic sorting and pathological missorting of Tau are isoform-specific and determined by axon initial segment architecture. The Journal of Biological Chemistry 17.
Zeitschriftenartikel
11 (12), e0167432 (2016)
Selection and characterization of tau binding D-enantiomeric peptides with potential for therapy of Alzheimer disease. PLoS One 18.
Zeitschriftenartikel
17 (4), S. 552 - 569 (2016)
The Tau/A152T mutation, a risk factor for frontotemporal-spectrum disorders, leads to NR2B receptor-mediated excitotoxicity. EMBO Reports 19.
Zeitschriftenartikel
113 (41), S. 11597 - 11602 (2016)
Adenosine A1 receptor antagonist rolofylline alleviates axonopathy caused by human Tau δK280. Proceedings of the National Academy of Sciences of the United States of America 20.
Zeitschriftenartikel
6, 22685 (2016)
Acetylation mimic of lysine 280 exacerbates human Tau neurotoxicity in vivo. Scientific Reports